The Role of Cancer-associated Fibroblasts in Renal Cell Carcinoma. An Example of Tumor Modulation Through Tumor/non-tumor Cell Interactions

Overview

Journal J Adv Res

Specialties General Medicine
Science

Date 2020 Feb 20

PMID 32071778

Citations 37

Authors

Peio Errarte

Gorka Larrinaga

Jose I Lopez

Affiliations

Soon will be listed here.

Abstract

Cancer-associated fibroblasts (CAF) are a cellular compartment of the tumor microenvironment (TME) with critical roles in tumor development. Fibroblast activation protein-α (FAP) is one of the proteins expressed by CAF and its immunohistochemical detection in routine practice is associated with tumor aggressiveness and shorter patient survival. For these reasons, FAP seems a good prognostic marker in many malignant neoplasms, including renal cell carcinoma (RCC). The start point of this paper is to review the role of CAF in the modulation of renal cell carcinoma evolution. In this sense, CAF have demonstrated to develop important protumor and/or antitumor activities. This apparent paradox suggests that some type of temporally or spatially-related specialization is present in this cellular compartment during tumor evolution. The end point is to remark that tumor/non-tumor cell interactions, in particular the symbiotic tumor/CAF connections, are permanent and ever-changing crucial phenomena along tumor lifetime. Interestingly, these interactions may be responsible of many therapeutic failures.

Citing Articles

Spatial expression of fibroblast activation protein-α in clear cell renal cell carcinomas revealed by multiplex immunoprofiling analysis of the tumor microenvironment.

Larrinaga G, Redrado M, Loizaga-Iriarte A, Perez-Fernandez A, Santos-Martin A, Angulo J Cancer Immunol Immunother. 2025; 74(2):53.

PMID: 39751643 PMC: 11699175. DOI: 10.1007/s00262-024-03896-y.

A computational analysis of the oncogenic and anti-tumor immunity role of P4HA3 in human cancers.

Huang H, Zhang F, Yu J, Xiao Y, Zhu D, Yi X PLoS Comput Biol. 2024; 20(11):e1012284.

PMID: 39504328 PMC: 11573185. DOI: 10.1371/journal.pcbi.1012284.

New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.

Cesana B, Cochet C, Filhol O Int J Cancer. 2024; 156(3):475-487.

PMID: 39306698 PMC: 11622000. DOI: 10.1002/ijc.35181.

Heterogeneity and function of cancer-associated fibroblasts in renal cell carcinoma.

Tang H, Xu W, Lu J, Anwaier A, Ye D, Zhang H J Natl Cancer Cent. 2024; 3(2):100-105.

PMID: 39035728 PMC: 11256550. DOI: 10.1016/j.jncc.2023.04.001.

A comprehensive review of 3D cancer models for drug screening and translational research.

Sharma K, Dey S, Karmakar R, Rengan A Cancer Innov. 2024; 3(1):e102.

PMID: 38948533 PMC: 11212324. DOI: 10.1002/cai2.102.

References

Hofheinz R, Al-Batran S, Hartmann F, Hartung G, Jager D, Renner C . Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003; 26(1):44-8. DOI: 10.1159/000069863. View

Mitsunari K, Miyata Y, Watanabe S, Asai A, Yasuda T, Kanda S . Stromal expression of Fer suppresses tumor progression in renal cell carcinoma and is a predictor of survival. Oncol Lett. 2017; 13(2):834-840. PMC: 5351384. DOI: 10.3892/ol.2016.5481. View

Gilkes D, Semenza G, Wirtz D . Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014; 14(6):430-9. PMC: 4283800. DOI: 10.1038/nrc3726. View

Arina A, Idel C, Hyjek E, Alegre M, Wang Y, Bindokas V . Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc Natl Acad Sci U S A. 2016; 113(27):7551-6. PMC: 4941507. DOI: 10.1073/pnas.1600363113. View

Lopez J . Renal tumors with clear cells. A review. Pathol Res Pract. 2013; 209(3):137-46. DOI: 10.1016/j.prp.2013.01.007. View

Abel E, Masterson T, Karam J, Master V, Margulis V, Hutchinson R . Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol. 2017; 198(4):810-816. DOI: 10.1016/j.juro.2017.04.066. View

Zeisberg E, Potenta S, Xie L, Zeisberg M, Kalluri R . Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007; 67(21):10123-8. DOI: 10.1158/0008-5472.CAN-07-3127. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Srigley J, Delahunt B, Eble J, Egevad L, Epstein J, Grignon D . The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013; 37(10):1469-89. DOI: 10.1097/PAS.0b013e318299f2d1. View

10.

Feig C, Jones J, Kraman M, Wells R, Deonarine A, Chan D . Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013; 110(50):20212-7. PMC: 3864274. DOI: 10.1073/pnas.1320318110. View

11.

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

12.

Chen X, Song E . Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018; 18(2):99-115. DOI: 10.1038/s41573-018-0004-1. View

13.

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

14.

Ferrara N . Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2009; 21(1):21-6. DOI: 10.1016/j.cytogfr.2009.11.003. View

15.

Wang L, Lo A, Scholler J, Sun J, Majumdar R, Kapoor V . Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014; 2(2):154-66. PMC: 4007316. DOI: 10.1158/2326-6066.CIR-13-0027. View

16.

Garin-Chesa P, Old L, Rettig W . Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990; 87(18):7235-9. PMC: 54718. DOI: 10.1073/pnas.87.18.7235. View

17.

Considine B, Hurwitz M . Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma. Curr Oncol Rep. 2019; 21(4):34. DOI: 10.1007/s11912-019-0779-1. View

18.

Errarte P, Guarch R, Pulido R, Blanco L, Nunes-Xavier C, Beitia M . The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases. PLoS One. 2016; 11(12):e0169105. PMC: 5199084. DOI: 10.1371/journal.pone.0169105. View

19.

Brinckerhoff C, Rutter J, Benbow U . Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2001; 6(12):4823-30. View

20.

Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun H, Ringert R . Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol. 1998; 160(5):1914-8. View